The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 25, 2023
Filed:
Dec. 08, 2020
Applicant:
Astellas Pharma Inc., Tokyo, JP;
Inventors:
Yuuki Takaishi, Tokyo, JP;
Soichiro Nakamura, Tokyo, JP;
Yutaka Takahashi, Tokyo, JP;
Takashi Nishizato, Tokyo, JP;
Daisuke Murayama, Tokyo, JP;
Emiko Murayama, Tokyo, JP;
Kazuhiro Sako, Tokyo, JP;
Assignee:
ASTELLAS PHARMA INC., Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/426 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/00 (2006.01); A61K 47/36 (2006.01); A61K 9/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/426 (2013.01); A61K 9/0004 (2013.01); A61K 9/1652 (2013.01); A61K 9/205 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2072 (2013.01); A61K 9/2086 (2013.01); A61K 9/2846 (2013.01); A61K 9/2866 (2013.01); A61K 47/36 (2013.01);
Abstract
A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.